Insider Trading March 24, 2026

BCP Investment Director Disposes of 37,100 Shares as Stock Nears 52-Week Low

Insider sale reduces holdings while company posts a modest earnings beat and faces analyst price-target cut

By Avery Klein BCIC
BCP Investment Director Disposes of 37,100 Shares as Stock Nears 52-Week Low
BCIC

Director Kehler Dean C sold 37,100 shares of BCP Investment Corp (NASDAQ: BCIC) on March 23, 2026, at prices between $7.36 and $7.42, generating proceeds of $273,694. The transaction leaves the director with 20,649 shares. The sale takes place while BCIC shares trade close to a 52-week low of $7.15 and are down 43% over the prior year. Separately, the company reported fourth-quarter 2025 results that beat EPS and revenue estimates, even as an analyst trimmed the price target amid mixed internal metrics.

Key Points

  • Director Kehler Dean C sold 37,100 BCIC shares on March 23, 2026 at $7.36 to $7.42, netting $273,694 and retaining 20,649 shares.
  • BCP Investment beat fourth-quarter 2025 EPS and revenue estimates but experienced a 5% decline in net asset value and a 7% operating return on equity.
  • Keefe, Bruyette & Woods cut its price target from $14.00 to $9.00 and kept a Market Perform rating despite the quarter's headline beats.

Director Kehler Dean C executed a sale of 37,100 shares of BCP Investment Corp common stock (NASDAQ: BCIC) on March 23, 2026. The trades were completed at prices ranging from $7.36 to $7.42, producing aggregate proceeds of $273,694. After the disposition, the director directly holds 20,649 shares.

The sale occurred while BCIC shares were trading near a 52-week low of $7.15 and after a 12-month decline of roughly 43% in the stock's market price.


Company financial update

BCP Investment Corporation reported fourth-quarter 2025 results that outpaced analysts' expectations on both earnings and revenue. The company posted earnings per share of $0.57, surpassing the forecast of $0.5325 by 7.04%. Revenue for the quarter came in at $17.5 million, compared with an expected $16.98 million.

Despite the quarterly EPS and revenue beats, Keefe, Bruyette & Woods reduced its price target for BCIC stock from $14.00 to $9.00 and retained a Market Perform rating. The firm cited a difficult fourth quarter in which net investment income fell short of expectations and the company recorded a 7% operating return on equity. Over the same period BCP Investment's net asset value declined by 5%.


Dividend and research note

According to InvestingPro data, BCIC currently offers a 21.75% dividend yield amid recent weakness in its share price. The InvestingPro platform also lists 12 additional ProTips for BCIC and provides a Pro Research Report that consolidates data into analytical output.


Analysis summary

The combination of an insider sale, shares trading near a yearlow, and a pronounced year-over-year share-price decline sits alongside an earnings and revenue beat and a substantial dividend yield. Analyst reaction to the quarter has been mixed, with at least one sell-side firm cutting its target and underscoring pressure on investment income and return metrics.


Key points

  • Kehler Dean C sold 37,100 BCIC shares on March 23, 2026 at $7.36 to $7.42, realizing $273,694; post-sale ownership is 20,649 shares.
  • BCP Investment beat fourth-quarter 2025 EPS ($0.57 vs. $0.5325 expected) and revenue ($17.5 million vs. $16.98 million expected).
  • Despite the beat, Keefe, Bruyette & Woods lowered its price target from $14.00 to $9.00 and kept a Market Perform rating, citing weaker net investment income, a 7% operating return on equity, and a 5% decline in net asset value.

Risks and uncertainties

  • Share-price weakness - BCIC is trading near a 52-week low ($7.15) and is down 43% over the past year, which may concern equity and income investors in the financials sector.
  • Operational pressure - a shortfall in net investment income and a modest 7% operating return on equity raise questions about near-term profitability metrics in the investment trust space.
  • Analyst sentiment - the downgrade of the price target to $9.00, despite a Market Perform rating, signals mixed analyst views that could affect investor demand for the stock.

Where available, investors should weigh the high dividend yield reported by InvestingPro against recent price and NAV trends. The facts set out here reflect the company's reported quarter, the insider transaction, and subsequent analyst comment cited above.

Risks

  • Market risk: BCIC shares trade near a 52-week low of $7.15 and are down 43% over the past year, which impacts equity and income investors in the financial sector.
  • Operational risk: Net investment income missed internal expectations in the reported quarter, and operating return on equity was 7%, affecting investment-performance metrics.
  • Analyst sentiment risk: A lowered price target from $14.00 to $9.00 by Keefe, Bruyette & Woods reflects mixed analyst confidence and could influence investor perception.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026